Skip to content

Vaxcyte, Inc. PCVX SWITZERLAND — PP&E (Net)

Other geography segments

UNITED STATES
$41.3M+2.0%

Similar metrics at other companies

Logitech International logo
LOGISwitzerland — Property, plant and equipment, net
$25M+3.7%
NOVA, Inc. logo
NOVOther Countries — PP&E (Net)
$781M+13.0%
Silicon Laboratories logo
SLABUnited States — PP&E (Net)
$105.86M-0.6%
Crocs logo
CROXInternational — PP&E (Net)
$43.48M+11.0%
Elanco Animal Health Inc. logo
ELANGermany — PP&E (Net)
$250M+8.7%
NOVA, Inc. logo
NOVUS — PP&E (Net)
$941M+1.4%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s switzerland — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s SWITZERLAND — PP&E (net)?
Vaxcyte, Inc. (PCVX) reported SWITZERLAND — PP&E (net) of $219.4M in Q1 2026.
How has Vaxcyte, Inc.'s SWITZERLAND — PP&E (net) changed year-over-year?
Vaxcyte, Inc.'s SWITZERLAND — PP&E (net) increased by 24.2% year-over-year, from $176.6M to $219.4M.
What does SWITZERLAND — PP&E (net) mean?
This metric represents the net book value of tangible assets, such as laboratory facilities, manufacturing equipment, and specialized infrastructure, located within the Swiss geographic segment. It reflects the company's capital investment in regional operational capacity and long-term physical assets used to support research, development, or production activities. Monitoring this balance helps investors assess the scale of physical footprint and the intensity of capital deployment in this specific international jurisdiction.